Advertisement
U.S. markets open in 4 hours 59 minutes
  • S&P Futures

    5,303.75
    -4.50 (-0.08%)
     
  • Dow Futures

    40,107.00
    -37.00 (-0.09%)
     
  • Nasdaq Futures

    18,491.00
    -12.75 (-0.07%)
     
  • Russell 2000 Futures

    2,134.10
    -4.30 (-0.20%)
     
  • Crude Oil

    81.78
    +0.43 (+0.53%)
     
  • Gold

    2,213.80
    +1.10 (+0.05%)
     
  • Silver

    24.55
    -0.20 (-0.82%)
     
  • EUR/USD

    1.0796
    -0.0034 (-0.31%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.97
    +0.19 (+1.49%)
     
  • GBP/USD

    1.2608
    -0.0030 (-0.24%)
     
  • USD/JPY

    151.3780
    +0.1320 (+0.09%)
     
  • Bitcoin USD

    70,490.79
    +627.15 (+0.90%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,951.56
    +19.58 (+0.25%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

HTG Molecular Diagnostics Announces $16 Million Term Loan Agreement With Silicon Valley Bank and Oxford Finance

TUCSON, AZ--(Marketwired - Aug 29, 2014) - HTG Molecular Diagnostics ("HTG") today announced that it has closed a growth capital term loan facility with Silicon Valley Bank and Oxford Finance (SVB/Oxford). The loan facility provides HTG with up to $16 million of available proceeds, with $11 million funded at the initial closing this month.

"Together with the capital raised through recent equity offerings, the debt facility with SVB/Oxford provides HTG the funding needed to pursue several operating initiatives, including key research and development (R&D) programs and strategic sales and marketing expansion," stated TJ Johnson, Chief Executive Officer of HTG.

"Oxford is very pleased to provide capital to support HTG's R&D programs and marketing strategies," said Christopher A. Herr, Managing Director for Oxford Finance. "The company is led by a seasoned management group, and we believe its molecular profiling platforms are highly innovative, with a wide range of applications."

"We are pleased to continue our decade-long partnership with HTG as the company advances and expands its R&D programs and sales initiatives," said Michael White, Managing Director of Silicon Valley Bank's Southwest Life Sciences team. "HTG's innovations have a direct and meaningful impact on patient lives and we are fortunate to be able to support the team with this new round of financing."

About HTG:

Headquartered in Tucson, Arizona, HTG's mission is to provide simple, cost effective solutions for accurate RNA testing. In 2013 the company commercialized its Edge instrument platform and a portfolio of mRNA assays that leverage HTG's proprietary nuclease protection chemistry. The capability of the Edge system has been expanded to fully automate sample and targeted library preparation for next-generation sequencing.

Advertisement